Future directions for antibody-drug conjugates in urothelial cancer
ADCs are rising as a cornerstone in UC, but important challenges remain. Future perspectives point toward the development of combination strategies and next-generation ADCs, designed to overcome resistance, minimize toxicity, and enhance selectivity.
Authors
- Roberto Sabbatini (ORCID: https://orcid.org/0000-0002-8943-7545)
- Massimo Dominici (ORCID: https://orcid.org/0000-0002-4007-1503)
- Elisa D’Agostino (ORCID: https://orcid.org/0009-0003-3060-6169)
- Cinzia Baldessari (ORCID: https://orcid.org/0000-0003-3051-8057)
- Marco Oltrecolli
- Francesca Bacchelli
- Maria Giuseppa Vitale (ORCID: https://orcid.org/0000-0001-8551-266X)
- Claudia Piombino (ORCID: https://orcid.org/0000-0002-7224-4536)
- Stefania Pipitone (ORCID: https://orcid.org/0000-0003-2677-1877)
- Marta Pirola
- Ornella Ponzoni
- Cyrielle Tchawa
- Elena Tonni
- Rossana Matranga
- V. Callegari
Institutions
- University of Modena and Reggio Emilia (IT)
- Azienda Unita' Sanitaria Locale Di Modena (IT)
Publication Details
- Journal
- Expert Review of Anticancer Therapy
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1080/14737140.2025.2592735
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00